Arylazanylpyrazolone Derivatives as Inhibitors of Mutant Superoxide Dismutase 1 Dependent Protein Aggregation for the Treatment of Amyotrophic Lateral Sclerosis

Yinan Zhang,[†] Radhia Benmohamed,[‡] He Huang,[†] Tian Chen,[†] Cindy Voisine,[§,||] Richard I. Morimoto,[§] Donald R. Kirsch,[‡] and Richard B. Silverman*[,†]

[†]Department of Chemistry and Department of Molecular Biosciences, Chemistry of Life Processes Institute, Center for Molecular Innovation and Drug Discovery, Northwestern University, Evanston, Illinois 60208-3113, United States

[‡]Cambria Pharmaceuticals, Cambridge, Massachusetts 02142, United States

[§]Department of Molecular Biosciences, Rice Institute for Biomedical Research, Northwestern University, Evanston, Illinois 60208-3500, United States

Ⓢ *Supporting Information*

ABSTRACT: The arylsulfanylpyrazolone and aryloxanylpyrazolone scaffolds previously were reported to inhibit Cu/Zn superoxide dismutase 1 dependent protein aggregation and to extend survival in the ALS mouse model. However, further evaluation of these compounds indicated weak pharmacokinetic properties and a relatively low maximum tolerated dose. On the basis of an ADME analysis, a new series of compounds, the arylazanylpyrazolones, has been synthesized, and structure−activity relationships were determined. The SAR results showed that the pyrazolone ring is critical to cellular protection. The NMR, IR, and computational analyses suggest that phenol-type tautomers of the pyrazolone ring are the active pharmacophore with the arylazanylpyrazolone analogues. A comparison of experimental and calculated IR spectra is shown to be a valuable method to identify the predominant tautomer.

INTRODUCTION

Amyotrophic lateral sclerosis (ALS), a rapidly fatal neurodegenerative disease, is characterized by progressive loss of upper and/or lower neurons in the motor cortex, brainstem, and ventral spinal cord.[1] Although the incidence and prevalence of the disease are relatively low compared with other neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease, it has the most rapid progression to death, in most cases within 3−5 years after diagnosis.[2] Moreover, an observed increased prevalence,[3] higher risk for military personnel,[4] and high cost for care in the late stages of ALS[5] result in extreme economic and emotional burdens to the patients and their families, nearly one-third of whom reside in the United States.[6] The sole FDA-approved drug riluzole, a presumptive antiglutamatergic agent, extends survival by only 2−3 months.[7]

Although the mechanistic basis of ALS and the cause of motor neuron death remain controversial, a cohort of susceptibility genes producing ALS have been identified from familial ALS patients,[8] such as fused in sarcoma, senataxin, TAR DNA binding protein (TDP-43), and UBQLN2. The discovery of the toxicity of mutant Cu/Zn superoxide dismutase 1 (SOD1) provides the first insight into potential causes for ALS[9] and contributes the most to our understanding of ALS pathology, which includes calcium mediated excitotoxicity, oxidative stress, mitochondrial dysfunction, and aberrant RNA processing.[10] Recent observations that mutant SOD1-expressing astrocytes are toxic to motor neurons in both familial and sporadic ALS,[11,12] together with the fact that SOD1 mediated protein misfolding and aggregation have proven to be associated with ALS pathogenesis,[13] suggest a possible therapeutic treatment involving protection against mutant SOD1-induced cytotoxicity. We therefore developed an assay using PC12 cells expressing G93A SOD1[14] and carried out a high-throughput screen to identify compounds that protected these cells from protein aggregation and toxicity.[15] One of the hit scaffolds was the arylsulfanylpyrazolones (ASPs), which exhibited good in vitro potency but was rapidly metabolized.[16] The metabolic hot spot was identified as the sulfur atom, which was readily oxidized. Conversion to the corresponding ether led to much more stable compounds, and one analogue extended the life of G93A ALS mice by 13.3% at 20 mg/kg.[17] A SAR study characterized the important parts of this class of compounds.[18] In a search of more potent and metabolically stable compounds, which also would allow diverse substitutions to carry out target identification studies, we synthesized the corresponding arylazanylpyrazolones (AAPs). These compounds are the focus of this paper (Figure 1).

RESULTS AND DISCUSSION

Chemistry. Two synthetic strategies were utilized to synthesize β-ketoesters, the critical intermediate for the construction of the pyrazolone ring. As shown in Scheme 1,

Figure 1. Substructures of AAP analogues.

the upper route started from the reaction of alkylanilines or sulfonylamides with ethyl bromoalkanoate. The ester intermediates reacted with the enolate of ethyl acetate, providing the anilino substituted β-ketoesters in moderate to high yields. The lower single-step route was carried out using an optimized methodology[19] based on the reaction of the aniline with ethyl 4-chloroacetoacetate, resulting in a series of anilino substituted β-ketoester intermediates with varied R and R′ substituents. All of the β-ketoester intermediates were transformed to pyrazolones in high yields with hydrazine.

An alternative synthetic route (Scheme 2) was designed for bulky R groups such as *tert*-butyl, phenyl, and benzyl, which gave low yields of anilino esters in the reaction above. By employment of ethyl diazoacetate, an NH insertion occurred to achieve the anilino esters in good yields,[20] which were used to generate the β-ketoester intermediates by attack of the enolate of ethyl acetate.

The N^1-methylpyrazolone analogue (30) was easily obtained by replacing hydrazine with methylhydrazine in the heterocycle formation (Scheme 3). The N^1-methylpyrazolones can be further modified to dimethyl- and trimethyl-substituted pyrazolone analogues (32−34). Although it has been reported that the condensation between methylhydrazine and a β-ketoester produces a mixture of N^1-alkyl and N^2-alkyl isomers,[21] no N^1-alkyl product was observed with our substrate. With the help of a method developed by Janin and co-workers,[22] our attempts to synthesize the N^2-alkyl product (31) were successful, as shown in Scheme 3. The β-ketoester intermediate was initially converted to N^1-2-hydroxylethyl-N^2-tosylpyrazolone derivative 35 in an 85% yield, which was then treated with sodium hydride to give key intermediate 36 containing a 2,3-dihydropyrazolo[3,2-*b*]oxazole ring. Alkylation with MeOTf and dihydrooxazole ring-opening with sodium iodide followed by elimination of hydrogen iodide led to N^1-vinyl-N^2-methylpyrazolone 37 in a 55% yield. Acid hydrolysis gave the desired N^1-methylpyrazolone analogue (31).

In Vitro Activity of Secondary and Tertiary AAPs. Compound 1 has an oral bioavailability of 27%, PK half-life of 3.6 h, and maximum tolerated dose of 75 mg/kg, which meet the standard minimal criteria for preclinical advancement.[23] However, some pharmacokinetic properties of 1 need improvement. For example, as indicated by the oral bioavailability,[17] the AUC/dose of 1 showed a distinct difference between iv (184

(ng·h/mL)/dose) and po (50 (ng·h/mL)/dose) administration. Given good aqueous solubility and cell permeability, one of the most likely causes for the difference between these two routes of administration is the first-pass clearance from hepatic and gut metabolism.[24] To increase metabolic stability and further diversify the structure, the ether oxygen was replaced by the isosteric amine functional group.

Two possible amines, secondary and tertiary AAP analogues, were initially screened in the protection assay (Figure 2) and for in vitro microsomal stability (Table 1) and Caco-2 permeability (Table 2). Introduction of the nitrogen led to a potency decrease in the cell-based protection assay; however, the tertiary arylazanyl analogue had a slightly better activity over the secondary arylazanyl analogue. The solubilities of 2 and 3 were good in aqueous media ($\geq$150 μM), and no precipitation occurred at the highest concentration. The in vitro plasma half-life for both compounds was >60 min. Tertiary amine 3 exhibited a remarkable stability enhancement in human liver microsomes compared with the moderate half-lives and clearance rates of the ether and secondary amine analogues. Whereas 1 had excellent permeability and low efflux potential toward Caco-2, neither 2 nor 3 exhibited satisfactory Caco-2 permeability and both had high efflux potential, although 3 was superior to 2.

These preliminary results suggest that the AAPs may not be an improvement over the aryloxanylpyrazolone series, but the tertiary amine analogue (3) showed improved human microsome stability, so a library of tertiary amine analogues was synthesized.

SAR of AAP Analogues. Compound activity was determined using the previously described cytotoxicity protection assay (Table 1, Supporting Information).[15] The variability of the EC$_{50}$ values is about a factor of 2. As shown in Figure 1, the tertiary amine AAP scaffold contains four substructural moieties: aromatic ring, N-substituent, linker, and the pyrazolone. Structural modifications were conducted on each moiety. A variety of substituents in the aryl moiety was investigated using our previous synthetic method for amination of anilines and γ-halogen-β-ketoesters (Figure 3). In general, the potencies of these AAPs were slightly poorer than those of the ether counterparts (1 vs 3[25]). Our previous reports on arylsulfanyl-[16] and aryloxanylpyrazolones[17] (AXP) showed that the 3,5-dichloro substitution pattern in the aromatic ring gave greater potency over the other substitution patterns (about 5- to 10-fold enhancement). Here, neither the electronic properties (compounds 4−6) nor the positions of substitution (compounds 9−11) in the aromatic ring exhibited a large activity change, but the size of the substituents affected the activity in the following order: F < CN < OMe < Cl ~ Br < di-Cl ~ naphthalene. 2,4-Dichloro- and α-naphthyl substitutions in the aromatic ring moiety were the most effective.

Scheme 1. Synthetic Routes for Arylazanylpyrazolones

Scheme 2. Synthesis of β-Ketoester Intermediates with Bulky R Groups

Scheme 3. Synthesis of Analogues Substituted on the Pyrazolone Moiety

Figure 2. Conversion of ether linker to amine linker.

Table 1. In Vitro Microsomal Stability of 1–3[a]

	NADPH-dependent		NADPH-absent	
compd	CL_{int}[b] (mL min^{-1} kg^{-1})	$T_{1/2}$[c] (min)	CL_{int}[b] (mL min^{-1} kg^{-1})	$T_{1/2}$[c] (min)
	Human			
1	25	93	13	173
2	24	95	0	>180
3	0	>180	0	>180
	Mouse			
1	64	36	21	111
2	78	30	23	100
3	93	25	0	>180

[a]Data were obtained from Apredica. [b]Microsomal intrinsic clearance. [c]Half-life.

Table 2. In Vitro Caco-2 Permeability of 1−3[a]

compd	$P_{app}(A{\to}B)$[b] (10^{-6} cm/s)	$P_{app}(B{\to}A)$[b] (10^{-6} cm/s)	efflux ratio (B→A)/(A→B)
1	36.7	14.1	0.4
2	0.6	28.1	47.1
3	2.2	7.6	3.5

[a]Data were obtained from Apredica. [b]Apparent permeability.

With the aromatic ring substituents, linker, and pyrazolone held constant, a series of N-substituted AAPs was synthesized

(Figure 4; these compounds were being synthesized prior to the measurements in Figure 3, so 3,5-dichloro was selected for aryl substitution). Although the range of potency changed by less than 4-fold, the ethyl analogue was the most potent and the potency decreased with an increase of the size of substituents in the following order: Et > c-Pr > i-Pr ~ Bn > propargyl > t-Bu ~ Ph; however, the smaller methyl analogue was comparable in potency to the cyclopropyl analogue. The propargyl analogue will be beneficial to our ongoing target identification studies, providing a terminal triple bond for reporter group attachment via click chemistry.[26]

An investigation of the linker between the aryl moiety and the pyrazolone also was carried out to determine the influence of length and shape. As shown in Figure 5, one carbon is the optimal length between the nitrogen and the pyrazolone moiety; longer linkers reduce the activity.

One useful modification to enhance the pharmacokinetic properties is a ring−chain transformation.[27] Four ring linkers were introduced to the AAP scaffold (25−28). The connection between the aryl group and the N-substituent (25 and 26) favored 26. The linker between the N-substituent and the pyrazolone ring (27 and 28) has a preference for that described by 28. The latter two compounds reveal that substitution at the 5-position of the pyrazolone does not affect potency.

Selected compounds were tested with cortical neurons, which is critical prior to the expensive and time-consuming ALS

**Figure 3.** AAP analogues with different substituents in the aromatic moiety.

**Figure 4.** AAP analogues with different N-substituents.

Figure 5. AAP analogues with different linkers.

mouse model studies.[28] Although long linker compound **24** and cyclic linker compound **27** are active in the PC12 assay, they are not active with cortical neurons. Compound **3** gave better results than the ether counterpart (**1**), recovering 100% neuronal activity at 10 μM (Supporting Information).

Pharmacophoric Nature of the Pyrazolone Ring. According to our previous studies, the pyrazolone ring is the key functional group for activity in all of the AXP scaffolds. The compounds without a pyrazolone or with N,N'-dimethyl substituted pyrazolone in the aryloxanyl series had no activity.[17] Given that there are three potential H-bonding donors/ acceptors in the pyrazolone ring, a determination of their pharmacophoric nature is important. In our recent paper,[18] a putative explanation for the pyrazolone activity was the

availability of the N^2-hydrogen (**3a**-type, Figure 7) for hydrogen bonding. To determine if the same moiety was essential for the AAP class of compounds, single N^2-nitrogen substituted pyrazolone analogue **31** and other substituted pyrazolone analogues were synthesized (Scheme 3). As shown in Figure 6, **29** and **30** were comparable in activity to parent

Figure 6. AAP analogues with different pyrazolone substitutions.

compound **3**, while compounds **31−34**, all of which do not have a N^2-H, were devoid of activity, demonstrating the significance of the N^2-H for activity in this series as well.

Several spectrometric analyses were carried out to determine if the pyrazolone structure shown in Figure 7 is the most prevalent. Because of a rapid equilibrium among the pyrazolone tautomers, the ^{13}C NMR spectrum of **3** gave a carbon signal with obscure bumps in the region of the pyrazolone and methylene group. However, clear ^{13}C NMR spectra of those

Figure 7. Tautomerism, HMBC, and NOE spectral results of compounds **3**, **30**, and **31**.

carbons in **30** and **31** suggested a predominant tautomer. HSQC, HMBC, and NOE spectra of **30** and **31** were then collected. The HSQC spectrum permitted the assignment of all of the protons with their bonding carbons. Analysis of the HMBC spectrum enabled the connectivity of the phenyl, the linker, and the pyrazolone moieties. The cross peaks between the phenol hydrogen and the 4-hydrogen of the pyrazolone in the NOE spectrum determined the spatial approach of these two neighboring hydrogens, which supported the predominant tautomer in **30** and **31** as the phenol form (**30b** and **31b**, Figure 7).

In an attempt to rationalize these observations, comprehensive theoretical calculations were performed on the four possible tautomers of **3** using density-functional theory (DFT); the predicted energy order was **3d** < **3b** < **3c** < **3a** in the gas phase (Table 3). The largest energy difference among

Table 3. Calculated Energies of the Tautomers of 3

tautomer	energy (au)	ΔE (kJ/mol)
3a	−1585.125 802	22.60
3b	−1585.129 852	11.97
3c	−1585.128 450	15.64
3d	−1585.134 409	0

all of the forms is 22.6 kJ/mol, which is an insufficient energy barrier to detect a preferred tautomeric form. Since the tautomerization of pyrazolone was first discovered by Knorr in 1895,[29] several reported calculations have predicted a similar prediction for the stability of the pyrazolone tautomers,[30] and calculations of similar structures predicted that the phenol forms are favored for 1- or 2-substituted pyrazolones in aprotic solvents,[20,31] as we observed.

To further characterize the predominant tautomeric form of the pyrazolone heterocycles in **30** and **31**, we performed quantum chemical calculations (Figure 8). The predominant conformation can be identified by comparing the experimental IR spectra with the predicted IR spectra of the different tautomers. All of the predicted spectra of keto tautomers have a similar high frequency at ∼1730 cm^{-1}, while the spectra of phenol-type tautomers have no absorption band in the same region. Hence, the frequency at ∼1730 cm^{-1}, the stretching vibration of the C=O bond, is an important band to

differentiate these two tautomers. The experimental IR spectra do not contain a band at 1730 cm^{-1}. Furthermore, the most highly predictive bands for phenol forms are in good agreement with the experimental data. All of these results indicate that phenol forms of **30** and **31** are the more stable tautomers. Similar NOE and IR spectral observations for ether analogue **38**[32] suggest that the active pyrazolone tautomer in the AOP series also is the phenol form (see Supporting Information and Figure 8C).

On the basis of the above results, we conclude that the pyrazolone phenol-type tautomer is predominant in solution and in solid phase, but given that the target(s) is unknown, we cannot conclude definitively whether this tautomer is the pharmacophoric core responsible for the activity of all AAP and AOP analogues. If that tautomer is the active tautomer, then biological activity requires the following two criteria: (1) N^2 has unsubstituted sp^2 hybridization rather than sp^3 hybridization; (2) there is a phenol hydrogen, presumably as a H-bonding donor. The loss of activity by di- and trimethyl substituted derivatives also supports the hypothesis that both criteria must be met for activity.

■ CONCLUSION

Aryloxanyl analogues were previously identified as potential drug candidates exhibiting good potency, ADME properties, and equivalent or slightly better results with the ALS mouse model as did the FDA-approved drug riluzole. However, because of its structural limitations, the aryloxanyl analogues may not be suitable as a chemical probe for a biological target study and need further optimization to improve in vivo activity.

The AAP analogues showed superior properties relative to the corresponding ether derivative in potential structural diversity and in preliminary metabolic studies. Conclusions from the SAR study are as follows: (1) the size of the aryl moiety, rather than the electronic properties, is important for good potency; (2) potency decreases when the size of the N-substituents increase; as a potential chemical reporter, the alkynyl group is well tolerated; (3) one carbon is the optimum length for the linker; the linker can be linear or cyclic; (4) the pyrazolone moiety is the only critical pharmacophore of this structure for activity, which prefers the phenol-type tautomer in solution and solid phase, although it is not known if it binds to any targets in that form; (5) a comparison of the predicted and

Figure 8. Experimental and calculated IR spectral comparison: (A) compound **30**; (B) compound **31**; (C) compound **38**; (i) experimental IR recorded in the solid phase; (ii) experimental IR recorded in DMSO solution; (iii) calculated IR of ketone-type tautomer (**30a**-like); (iv) calculated IR of phenol-type tautomer (**30b**-like). The stretching vibrations of the C=O bond (~1730 cm^{-1}) and skeletal vibrations of the aromatic rings (1600–1550 cm^{-1}) are given in red.

experimental IR spectra is useful to identify the predominant tautomer of a heterocyclic system.

These results support further development of AAP analogues as a reagent for target identification and as a novel drug candidate for the treatment of ALS.

■ EXPERIMENTAL SECTION

General Experimental Methods. All reactions were carried out with magnetic stirring and were monitored by thin-layer chromatography on precoated silica gel 60 F254 plates. Column chromatography was performed with silica gel 60 (230–400 mesh). Proton and carbon NMR spectra were recorded in deuterated solvents on a Bruker Ag500 (500 MHz) spectrometer. The chemical shifts were reported in δ (ppm) (^{1}H NMR: CDCl$_3$, δ 7.26 ppm; DMSO-d_6, δ 2.50 ppm. ^{13}C NMR: δ 77.23 ppm; DMSO-d$_6$, δ 39.52 ppm). The following abbreviations were used to define the multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, p = pentet, m = multiplet. Electrospray mass spectra were obtained using an Agilent 1100 MSD instrument with methanol as the solvent in the positive ion mode. IR was recorded on a Bruker TENSOR FT-IR spectrometer. Elemental microanalysis was performed by Atlantic Microlab Inc. (Norcross, GA). The C, H, and N analyses were performed by combustion using automatic analyzers, and all of the compounds analyzed showed >95% purity. All reagents purchased from Aldrich, Alfa Aesar, and TCI were used without further purification unless stated otherwise.

General Procedure A for Nucleophilic Amination of Anilines and Bromoacetates. To a solution of K$_2$CO$_3$ (200 mol %) and the aniline (1.0 equiv) in DMF (2 mL/mmol) was added ethyl bromoacetate (150 mol %). The reaction mixture was stirred at room temperature or 80 °C for 16 h. The reaction solution was diluted with ethyl acetate, washed twice with water to remove the reaction solvent, and washed with brine. The collected organic layers were combined, dried over Na$_2$SO$_4$, filtered, and concentrated. The crude product was purified on a silica gel column, eluting with a mixture of ethyl acetate and hexane (5–20% ethyl acetate) to afford the product as a colorless to pale yellow oil in a yield of 30–80%.

General Procedure B for Carbene Insertion of Anilines. To a solution of the aniline (1.0 equiv) and Rh$_2$(OAc)$_4$ (2 mol %) in anhydrous dichloromethane (1 mL/mmol) was added ethyl diazoacetate dropwise. Caution: Much N$_2$ is released! The reaction mixture was stirred at room temperature for 1 h. After evaporation of the volatiles, the reaction residue was purified on a silica gel column, eluting with a mixture of ethyl acetate and hexane (5–20% ethyl

acetate) to afford the product as a colorless to pale yellow oil in a yield of 50–95%.

General Procedure C for the Synthesis of β-Ketoesters from Aminoacetates. Ethyl acetate (110 mol %) was added to a THF (5 mL/mmol) solution of LiHMDS (1 N in THF, 120 mol %) at −78 °C and stirred for 60 min. A THF (1 mL/mmol) solution of β-aminoacetate (1.0 equiv) was added dropwise to the reaction mixture at −78 °C. After the resulting solution was stirred at −78 °C for another 2 h, the reaction mixture was quenched with saturated NH$_4$Cl. The aqueous layer was extracted with ethyl acetate and washed twice with water and brine. The collected organic layers were combined, dried over Na$_2$SO$_4$, filtered, and concentrated. The crude product was purified on a silica gel column, eluting with a mixture of ethyl acetate and hexane (10–30% ethyl acetate) to afford the product as a colorless to pale yellow oil in a yield of 40–80%.

General Procedure D for Direct Amination of γ-Halo-β-ketoesters with Anilines. To a solution of NaHCO$_3$ (200 mol %), NaI (200 mol %), and the aniline (1 equiv) in acetonitrile (1 mL/mol) was added ethyl α-chloracetoacetate (200 mol %). The resulting reaction mixture was stirred at room temperature or at 80 °C for 1–16 h. After the mixture was cooled to room temperature, saturated Na$_2$S$_2$O$_3$ solution (1 mL/mol) was added. The resulting solution was extracted with ethyl acetate, and the organic layer was collected, which was then washed with water and brine. The collected organic layers were combined, dried over Na$_2$SO$_4$, filtered, and concentrated. The residue was subjected to column chromatography, eluting with a mixture of hexane and ethyl acetate (10–30% ethyl acetate) to afford the product as a pale yellow oil in a yield specified in the our published method of amination.[19]

General Procedure E for the Synthesis of Pyrazolones from β-Ketoesters. To a solution of β-ketoesters (1 equiv) in EtOH (5 mL/mmol) was added anhydrous hydrazine (200 mol %). The resulting solution was stirred at room temperature overnight. After evaporation of the volatiles, the reaction residue was purified on a silica gel column, eluting with a mixture of MeOH and dichloromethane (2–10% MeOH) to afford the product as a colorless to pale pink solid. The solid was then recrystallized in dichloromethane/hexane to give the pure product as a white solid in a yield of 60–75%.

5-((3,5-Dichlorophenylamino)methyl)-1H-pyrazol-3(2H)-one (2). Following general procedures A, C, and E provided the phenylsulfonyl protected *N*-(3,5-dichlorophenyl)-*N*-((5-oxo-2,5-dihydro-1H-pyrazol-3-yl)methyl)benzenesulfonamide. ^{1}H NMR (DMSO-d_6, 500 MHz): δ = 11.56 (br s, 1H), 9.45 (br s, 1H), 7.78–7.74 (m, 1H), 7.64–7.63 (m, 4H), 7.56 (s, 1H), 7.14 (d, *J* = 1.5 Hz, 2H), 5.21

(s, 1H), 4.67 (s, 2H). ^{13}C NMR (DMSO-d_6, 125 MHz): δ = 140.8, 136.6, 133.8 × 2, 133.7 × 2, 129.6 × 2, 127.6 × 2, 127.5, 127.0 ppm. MS (ESI): m/z 398.0 [M + H]$^+$.

N-(3,5-Dichlorophenyl)-*N*-((5-oxo-2,5-dihydro-1*H*-pyrazol-3-yl)-methyl)benzenesulfonamide (398 mg, 1 mmol) and 4-hydroxybenzoic acid (800 mg, 5.8 mmol, 200% weight) were added to a solution of HBr (48% in H$_2$O, 4 mL) and AcOH (4 mL). After the resulting suspension was stirred at 100 °C for 2 h, the reaction mixture was partitioned between 1 N HCl (10 mL) and ethyl acetate (30 mL × 2). The collected organic layers were combined, dried over Na$_2$SO$_4$, filtered, and concentrated. The residue was subjected to column chromatography, eluting with a mixture of MeOH and dichloromethane (5% MeOH) to afford **2** (142 mg, 55% yield) as a white solid. ^{1}H NMR (DMSO-d_6, 500 MHz): δ = 6.65 (t, J = 5.5 Hz, 1H), 6.61 (s, 1H), 6.59, (s, 2H), 5.35 (s, 1H), 4.10 (d, J = 5.0 Hz, 2H). ^{13}C NMR (DMSO-d_6, 125 MHz): δ = 150.7, 134.3 × 2, 114.6, 110.4 × 2 ppm. MS (ESI): m/z 280.0 [M + Na]$^+$. CHN calculated for C$_{10}$H$_9$Cl$_2$N$_3$O: C, 46.53; H, 3.51; N, 16.28. Found: C, 46.44; H, 3.61; N, 16.36.

5-(((3,5-Dichlorophenyl)(methyl)amino)methyl)-1*H*-pyrazol-3(2*H*)-one (3). The title compound was prepared according to general procedures D and E. ^{1}H NMR (DMSO-d_6, 500 MHz): δ = 9.93 (br s, 1H), 6.72 (m, 3H), 5.24 (s, 1H), 4.40 (s, 2H), 2.96 (s, 3H). ^{13}C NMR (DMSO-d_6, 125 MHz): δ = 150.8, 134.6 × 2, 114.8, 110.7 × 2, 88.1, 47.9, 38.6 ppm. MS (ESI): m/z 272.0 [M + H]$^+$. CHN calculated for C$_{11}$H$_{11}$Cl$_2$N$_3$O: C, 48.55; H, 4.07; N, 15.44. Found: C, 48.80; H, 4.13; N, 15.35.

5-((Methyl(phenyl)amino)methyl)-1*H*-pyrazol-3(2*H*)-one (4). The title compound was prepared according to general procedures D and E. ^{1}H NMR (DMSO-d_6, 500 MHz): δ = 7.15 (dt, J = 2.0, 7.5 Hz, 2H), 6.76 (d, J = 8.0 Hz, 2H), 6.63 (t, J = 7.5 Hz, 1H), 5.21 (s, 1H), 4.36 (s, 2H), 2.90 (s, 3H). ^{13}C NMR (DMSO-d_6, 125 MHz): δ = 149.0, 128.9 × 2, 116.3, 112.7, 88.4, 47.7, 38.3 ppm. MS (ESI): m/z 204.0 [M + H]$^+$. CHN calculated for C$_{11}$H$_{13}$N$_3$O: C, 65.01; H, 6.45; N, 20.68. Found: C, 64.98; H, 6.34; N, 20.68.

5-(((3-Methoxyphenyl)(methyl)amino)methyl)-1*H*-pyrazol-3(2*H*)-one (5). The title compound was prepared according to general procedures D and E. ^{1}H NMR (DMSO-d_6, 500 MHz): δ = 11.47 (br s, 1H), 9.36 (br s, 1H), 7.04 (t, J = 8.0 Hz, 1H), 6.35 (dd, J = 2.0, 7.5 Hz, 1H), 6.26−6.21 (m, 2H), 5.21 (s, 1H), 4.33 (s, 2H), 3.68 (s, 3H), 2.89 (s, 3H). ^{13}C NMR (DMSO-d_6, 125 MHz): δ = 160.2, 150.3, 129.6, 105.7, 101.6, 99.0, 88.8, 54.8, 38.4 ppm. MS (ESI): m/z 234.1 [M + H]$^+$. CHN calculated for C$_{12}$H$_{15}$N$_3$O$_2$: C, 61.79; H, 6.48; N, 18.01. Found: C, 61.77; H, 6.47; N, 18.09.

4-(Methyl((5-oxo-2,5-dihydro-1*H*-pyrazol-3-yl)methyl)-amino)benzonitrile (6). The title compound was prepared according to general procedures D and E. ^{1}H NMR (DMSO-d_6, 500 MHz): δ = 7.53 (d, J = 8.0 Hz, 2H), 6.82 (d, J = 8.0 Hz, 2H), 5.25 (s, 1H), 4.47 (s, 2H), 3.04 (s, 3H). ^{13}C NMR (DMSO-d_6, 125 MHz): δ = 151.6, 133.2 × 2, 120.4, 112.2 × 2, 38.4 ppm. MS (ESI): m/z 251.1 [M + Na]$^+$. CHN calculated for C$_{12}$H$_{12}$N$_4$O: C, 63.15; H, 5.30; N, 24.55. Found: C, 62.87; H, 5.35; N, 24.34.

5-(((4-Fluorophenyl)(methyl)amino)methyl)-1*H*-pyrazol-3(2*H*)-one (7). The title compound was prepared according to general procedures D and E. ^{1}H NMR (DMSO-d_6, 500 MHz): δ = 11.47 (br s, 1H), 9.34 (br s, 1H), 7.00 (t, J = 4.0 Hz, 2H), 6.75 (ddd, J = 2.5, 4.5, 11.0 Hz, 2H), 5.21 (s, 1H), 4.32 (s, 2H), 2.86 (s, 3H). ^{13}C NMR (DMSO-d_6, 125 MHz): δ = 160.3, 155.6, 153.8, 145.9, 141.5, 115.3, 115.1, 114.1, 114.0, 88.2, 48.5, 38.7 ppm. MS (ESI): m/z 222.1 [M + H]$^+$. CHN calculated for C$_{11}$H$_{12}$FN$_3$O: C, 59.72; H, 5.47; N, 18.99. Found: C, 59.53; H, 5.56; N, 18.96.

5-(((4-Chlorophenyl)(methyl)amino)methyl)-1*H*-pyrazol-3(2*H*)-one (8). The title compound was prepared according to general procedures D and E. ^{1}H NMR (DMSO-d_6, 500 MHz): δ = 7.16 (t, J = 8.5 Hz, 2H), 6.75 (d, J = 8.5 Hz, 2H), 5.20 (s, 1H), 4.36 (s, 2H), 2.90 (s, 3H). ^{13}C NMR (DMSO-d_6, 125 MHz): δ = 147.8, 128.5 × 2, 119.9, 114.1 × 2, 88.3, 47.9, 38.5 ppm. MS (ESI): m/z 238.1 [M + H]$^+$. CHN calculated for C$_{11}$H$_{12}$ClN$_3$O: C, 55.59; H, 5.09; N, 17.68. Found: C, 55.55; H, 5.17; N, 17.58.

5-(((4-Bromophenyl)(methyl)amino)methyl)-1*H*-pyrazol-3(2*H*)-one (9). The title compound was prepared according to general

procedures D and E. ^{1}H NMR (DMSO-d_6, 500 MHz): δ = 7.27 (d, J = 7.5 Hz, 2H), 6.70 (d, J = 7.5 Hz, 2H), 5.21 (s, 1H), 4.36 (s, 2H), 2.90 (s, 3H). ^{13}C NMR (DMSO-d_6, 125 MHz): δ = 148.1, 131.3 × 2, 114.7 × 2, 107.4, 88.1, 47.9, 38.4 ppm. MS (ESI): m/z 282.0 [M + H]$^+$. CHN calculated for C$_{11}$H$_{12}$BrN$_3$O: C, 46.83; H, 4.29; N, 14.89. Found: C, 46.93; H, 4.30; N, 14.87.

5-(((3-Bromophenyl)(methyl)amino)methyl)-1*H*-pyrazol-3(2*H*)-one (10). The title compound was prepared according to general procedures D and E. ^{1}H NMR (DMSO-d_6, 500 MHz): δ = 11.50 (br s, 1H), 9.45 (br s, 1H), 7.08 (t, J = 8.0 Hz, 1H), 6.86 (s, 1H), 6.75 (dt, J = 2.5, 8.0 Hz, 1H), 5.22 (s, 1H), 4.37 (s, 2H), 2.92 (s, 3H). ^{13}C NMR (DMSO-d_6, 125 MHz): δ = 150.3, 130.6, 122.6, 118.5, 114.6, 111.5, 38.4 ppm. MS (ESI): m/z 282.0 [M + H]$^+$. CHN calculated for C$_{11}$H$_{12}$BrN$_3$O: C, 46.83; H, 4.29; N, 14.89. Found: C, 46.92; H, 4.36; N, 14.87.

5-(((3-Bromophenyl)(methyl)amino)methyl)-1*H*-pyrazol-3(2*H*)-one (11). The title compound was prepared according to general procedures D and E. ^{1}H NMR (DMSO-d_6, 500 MHz): δ = 7.58 (dd, J = 1.0, 8.0 Hz, 1H), 7.30 (dt, J = 1.0, 8.0 Hz, 1H), 7.13 (dd, J = 1.0, 8.0 Hz, 1H), 6.97 (dt, J = 1.0, 8.0 Hz, 1H), 5.24 (s, 1H), 4.02 (s, 2H), 2.62 (s, 3H). ^{13}C NMR (DMSO-d_6, 125 MHz): δ = 150.0, 133.5, 128.4, 124.6, 122.6, 119.2, 39.0 ppm. MS (ESI): m/z 282.0 [M + H]$^+$. CHN calculated for C$_{11}$H$_{12}$BrN$_3$O: C, 46.83; H, 4.29; N, 14.89. Found: C, 46.86; H, 4.31; N, 14.88.

5-((Methyl(naphthalen-2-yl)amino)methyl)-1*H*-pyrazol-3(2*H*)-one (12). The title compound was prepared according to general procedures D and E. ^{1}H NMR (DMSO-d_6, 500 MHz): δ = 7.70 (t, J = 9.0 Hz, 2H), 7.64 (d, J = 8.5 Hz, 1H), 7.34−7.28 (m, 2H), 7.16 (dt, J = 1.0, 8.0 Hz, 1H), 6.97 (d, J = 2.0 Hz, 1H), 5.21 (s, 1H), 4.49 (s, 2H), 3.00 (s, 3H). ^{13}C NMR (DMSO-d_6, 125 MHz): δ = 147.0, 134.6, 128.4, 127.2, 126.4, 126.1, 126.0, 121.9, 116.7, 38.5 ppm. MS (ESI): m/z 254.1 [M + H]$^+$. CHN calculated for C$_{15}$H$_{15}$N$_3$O: C, 71.13; H, 5.97; N, 16.59. Found: C, 70.94; H, 6.02; N, 16.54.

5-((Methyl(naphthalen-1-yl)amino)methyl)-1*H*-pyrazol-3(2*H*)-one (13). The title compound was prepared according to general procedures D and E. ^{1}H NMR (DMSO-d_6, 500 MHz): δ = 8.27 (d, J = 8.0 Hz, 1H), 7.90 (dt, J = 1.5, 7.5 Hz, 1H), 7.59 (d, J = 8.0 Hz, 1H), 7.53−7.49 (m, 2H), 7.41 (t, J = 8.0 Hz, 1H), 7.14 (d, J = 7.0 Hz, 1H), 5.31 (s, 1H), 4.08 (s, 2H), 2.73 (s, 3H). ^{13}C NMR (DMSO-d_6, 125 MHz): δ = 149.0, 134.4, 128.5, 128.3, 125.9, 125.8, 125.4, 123.6, 123.1, 115.7, 39.0 ppm. MS (ESI): m/z 254.1 [M + H]$^+$. CHN calculated for C$_{15}$H$_{15}$N$_3$O: C, 71.13; H, 5.97; N, 16.59. Found: C, 71.29; H, 6.01; N, 16.51.

5-(((3,4-Dichlorophenyl)(methyl)amino)methyl)-1*H*-pyrazol-3(2*H*)-one (14). The title compound was prepared according to general procedures D and E. ^{1}H NMR (DMSO-d_6, 500 MHz): δ = 7.32 (d, J = 9.0 Hz, 1H), 6.91 (d, J = 3.0 Hz, 1H), 6.74 (dd, J = 3.0, 9.0 Hz, 1H), 5.22 (s, 1H), 4.39 (s, 2H), 2.94 (s, 3H). ^{13}C NMR (DMSO-d_6, 125 MHz): δ = 148.8, 131.3, 130.3, 117.3, 113.5, 112.9, 38.5 ppm. MS (ESI): m/z 272.0 [M + H]$^+$. CHN calculated for C$_{11}$H$_{11}$Cl$_2$N$_3$O: C, 48.55; H, 4.07; N, 15.44. Found: C, 48.55; H, 4.04; N, 15.46.

5-(((2,4-Dichlorophenyl)(methyl)amino)methyl)-1*H*-pyrazol-3(2*H*)-one (15). The title compound was prepared according to general procedures D and E. ^{1}H NMR (DMSO-d_6, 500 MHz): δ = 7.53 (d, J = 2.0 Hz, 1H), 7.31 (dd, J = 2.0, 8.5 Hz, 1H), 7.09 (d, J = 8.5 Hz, 1H), 5.20 (s, 1H), 4.05 (s, 2H), 2.64 (s, 3H). ^{13}C NMR (DMSO-d_6, 125 MHz): δ = 147.6, 129.7, 128.5, 127.6, 126.7, 123.3, 39.0 ppm. MS (ESI): m/z 272.0 [M + H]$^+$. CHN calculated for C$_{11}$H$_{11}$Cl$_2$N$_3$O: C, 48.55; H, 4.07; N, 15.44. Found: C, 48.33; H, 4.18; N, 15.21.

5-(((3,5-Dichlorophenyl)(ethyl)amino)methyl)-1*H*-pyrazol-3(2*H*)-one (16). The title compound was prepared according to general procedures D and E. ^{1}H NMR (DMSO-d_6, 500 MHz): δ = 6.67 (m, 3H), 5.26 (s, 1H), 4.34 (s, 2H), 3.42 (d, J = 7.0 Hz, 2H), 1.06 (t, J = 7.0 Hz, 3H). ^{13}C NMR (DMSO-d_6, 125 MHz): δ = 149.6, 134.6 × 2, 114.3, 110.2 × 2, 44.8, 11.8 ppm. MS (ESI): m/z 286.0 [M + H]$^+$. CHN calculated for C$_{12}$H$_{13}$Cl$_2$N$_3$O: C, 50.37; H, 4.58; N, 14.68. Found: C, 50.54; H, 4.58; N, 14.68.

5-(((3,5-Dichlorophenyl)(isopropyl)amino)methyl)-1*H*-pyrazol-3(2*H*)-one (17). The title compound was prepared according to general procedures B, C, and E. ^{1}H NMR (DMSO-d_6, 500 MHz): δ = 7.25−7.21 (m, 3H), 5.11 (s, 1H), 4.17 (s, 2H), 1.12 (m, 9H). ^{13}C

NMR (DMSO-d_6, 125 MHz): δ = 150.5, 134.5 × 2, 114.6, 110.9 × 2, 48.1, 19.5 × 2 ppm. MS (ESI): m/z 300.1 [M + H]$^+$. CHN calculated for $C_{13}H_{15}Cl_2N_3O$: C, 52.01; H, 5.04; N, 14.00. Found: C, 52.10; H, 5.19; N, 13.87.

5-((*tert*-Butyl(3,5-dichlorophenyl)amino)methyl)-1*H*-pyrazol-3(2*H*)-one (18). The title compound was prepared according to general procedures B, C, and E. ^{1}H NMR (DMSO-d_6, 500 MHz): δ = 6.68−6.67 (m, 3H), 5.22 (s, 1H), 4.25 (s, 2H), 4.17−4.15 (m, 1H), 1.13 (d, J = 7.0 Hz, 6H). ^{13}C NMR (DMSO-d_6, 125 MHz): δ = 151.4, 133.0 × 2, 127.4, 123.9, 55.7, 17.8 × 3 ppm. MS (ESI): m/z 314.1 [M + H]$^+$. CHN calculated for $C_{14}H_{17}Cl_2N_3O$: C, 53.52; H, 5.45; N, 13.37. Found: C, 53.45; H, 5.45; N, 13.40.

5-((Cyclopropyl(3,5-dichlorophenyl)amino)methyl)-1*H*-pyrazol-3(2*H*)-one (19). The title compound was prepared according to general procedures B, C, and E. ^{1}H NMR (DMSO-d_6, 500 MHz): δ = 9.42 (br s, 1H), 6.86 (s, 2H), 6.74 (s, 1H), 5.10 (s, 1H), 4.37 (s, 2H), 2.43 (s, 1H), 0.83−0.82 (m, 2H), 0.55 (s, 2H). ^{13}C NMR (DMSO-d_6, 125 MHz): δ = 151.3, 134.2 × 2, 116.1, 112.3 × 2, 88.4, 46.7, 32.2, 9.1 × 2 ppm. MS (ESI): m/z 298.0 [M + H]$^+$. CHN calculated for $C_{13}H_{13}Cl_2N_3O$: C, 52.37; H, 4.39; N, 14.09. Found: C, 52.33; H, 4.37; N, 14.89.

5-((Benzyl(3,5-dichlorophenyl)amino)methyl)-1*H*-pyrazol-3(2*H*)-one (20). The title compound was prepared according to general procedures B, C, and E. ^{1}H NMR (DMSO-d_6, 500 MHz): δ = 7.34 (t, J = 7.5 Hz, 2H), 7.25 (t, J = 7.5 Hz, 1H), 7.21 (d, J = 7.5 Hz, 2H), 6.70 (s, 1H), 6.68 (s, 2H), 5.32 (s, 1H), 4.66 (s, 2H), 4.52 (s, 2H). ^{13}C NMR (DMSO-d_6, 125 MHz): δ = 150.0, 137.8, 134.4 × 2, 128.6 × 2, 127.0, 126.4 × 2, 115.0, 110.8 × 2, 53.8 ppm. MS (ESI): m/z 298.0 [M + H]$^+$. CHN calculated for $C_{17}H_{15}Cl_2N_3O$: C, 58.63; H, 4.34; N, 12.07. Found: C, 59.01; H, 4.63; N, 11.83.

5-(((3,5-Dichlorophenyl)(phenyl)amino)methyl)-1*H*-pyrazol-3(2*H*)-one (21). The title compound was prepared according to general procedures B, C,[33] and E. ^{1}H NMR (DMSO-d_6, 500 MHz): δ = 11.59 (br s, 1H), 9.65 (br s, 1H), 7.43 (t, J = 7.0 Hz, 2H), 7.28−7.22 (m, 3H), 6.88 (s, 1H), 6.72 (s, 2H), 5.24 (s, 1H), 4.77 (s, 2H). ^{13}C NMR (DMSO-d_6, 125 MHz): δ = 150.0, 145.6, 134.4 × 2, 130.0 × 2, 125.8 × 2, 125.6, 117.2, 113.8 × 2 ppm. MS (ESI): m/z 334.0 [M + H]$^+$. CHN calculated for $C_{16}H_{13}Cl_2N_3O$: C, 57.50; H, 3.92; N, 12.57. Found: C, 57.70; H, 4.27; N, 12.94.

5-(((3,5-Dichlorophenyl)(prop-2-ynyl)amino)methyl)-1*H*-pyrazol-3(2*H*)-one (22). The title compound was prepared according to general procedures B, C, and E. ^{1}H NMR (DMSO-d_6, 500 MHz): δ = 6.82 (s, 3H), 5.35 (s, 1H), 4.41 (s, 2H), 4.21 (d, J = 2.0 Hz, 2H), 3.26 (d, J = 2.0 Hz, 1H). ^{13}C NMR (DMSO-d_6, 125 MHz): δ = 149.4, 134.4 × 2, 116.1, 111.8 × 2, 89.1, 79.6, 75.2 ppm. MS (ESI): m/z 296.1 [M + H]$^+$. CHN calculated for $C_{13}H_{11}Cl_2N_3O$: C, 52.72; H, 3.74; N, 14.19. Found: C, 52.63; H, 3.91; N, 13.92.

5-(2-((3,5-Dichlorophenyl)(methyl)amino)ethyl)-1*H*-pyrazol-3(2*H*)-one (23). The title compound was prepared according to general procedures A, C, and E. ^{1}H NMR (DMSO-d_6, 500 MHz): δ = 11.35 (br s, 1H), 9.41 (br s, 1H), 6.69 (d, J = 1.5 Hz, 1H), 6.66 (d, J = 2.0 Hz, 2H), 5.33 (s, 1H), 3.54 (t, J = 7.5 Hz, 2H), 2.85 (s, 3H), 2.64 (t, J = 7.5 Hz, 2H). ^{13}C NMR (DMSO-d_6, 125 MHz): δ = 150.4, 134.7 × 2, 114.3, 110.0 × 2, 88.7, 51.1, 37.9 ppm. MS (ESI): m/z 286.0 [M + H]$^+$. CHN calculated for $C_{12}H_{13}Cl_2N_3O$: C, 50.37; H, 4.58; N, 14.68. Found: C, 50.66; H, 4.80; N, 14.58.

5-(3-((3,5-Dichlorophenyl)(methyl)amino)propyl)-1*H*-pyrazol-3(2*H*)-one (24). The title compound was prepared according to general procedures B, C, and E. ^{1}H NMR (DMSO-d_6, 500 MHz): δ = 11.27 (br s, 1H), 9.30 (br s, 1H), 6.66 (d, J = 1.5 Hz, 1H), 6.61 (d, J = 1.5 Hz, 2H), 5.26 (s, 1H), 3.32 (t, J = 7.5 Hz, 2H), 2.88 (s, 3H), 2.45 (t, J = 7.5 Hz, 2H), 1.76−1.73 (m, 2H). ^{13}C NMR (DMSO-d_6, 125 MHz): δ = 150.7, 134.7 × 2, 114.0, 109.8 × 2, 50.9, 38.0, 25.4 ppm. MS (ESI): m/z 300.1 [M + H]$^+$. CHN calculated for $C_{13}H_{15}Cl_2N_3O$: C, 52.01; H, 5.04; N, 14.00. Found: C, 52.23; H, 5.14; N, 14.94.

5-(Indolin-1-ylmethyl)-1*H*-pyrazol-3(2*H*)-one (25). The title compound was prepared according to general procedures D and E. ^{1}H NMR (DMSO-d_6, 500 MHz): δ = 7.02 (d, J = 7.0 Hz, 1H), 6.98 (t, J = 7.5 Hz, 1H), 6.62 (d, J = 7.5 Hz, 1H), 6.58 (t, J = 7.5 Hz, 1H), 5.31 (s, 1H), 4.12 (s, 2H), 3.24 (t, J = 8.0 Hz, 2H), 2.85 (t, J = 8.0 Hz, 2H).

^{13}C NMR (DMSO-d_6, 125 MHz): δ = 151.7, 129.8, 127.0, 124.3, 117.5, 107.5, 89.0, 52.6, 44.0, 27.9 ppm. MS (ESI): m/z 216.1 [M + H]$^+$. CHN calculated for $C_{12}H_{13}N_3O$: C, 66.96; H, 6.09; N, 19.52. Found: C, 66.85; H, 6.11; N, 19.44.

5-((3,4-Dihydroquinolin-1(2*H*)-yl)methyl)-1*H*-pyrazol-3(2*H*)-one (26). The title compound was prepared according to general procedures D and E. ^{1}H NMR (DMSO-d_6, 500 MHz): δ = 6.91 (t, J = 7.0 Hz, 1H), 6.86 (d, J = 7.0 Hz, 1H), 6.64 (d, J = 8.5 Hz, 1H), 6.47 (t, J = 7.5 Hz, 1H), 5.26 (s, 1H), 4.28 (s, 2H), 3.28 (t, J = 5.5 Hz, 2H), 2.66 (t, J = 5.5 Hz, 2H), 1.87 (p, J = 6.0 Hz, 2H). ^{13}C NMR (DMSO-d_6, 125 MHz): δ = 144.9, 128.8, 126.7, 122.2, 115.8, 111.2, 88.4, 49.1, 46.5, 39.0, 27.5, 21.8 ppm. MS (ESI): m/z 216.1 [M + H]$^+$. CHN calculated for $C_{13}H_{15}N_3O$: C, 68.10; H, 6.59; N, 18.33. Found: C, 68.02; H, 6.60; N, 18.29.

5-(3,5-Dichlorophenyl)-4,5,6,7-tetrahydro-1*H*-pyrazolo[4,3-c]pyridin-3(2*H*)-one (27). The title compound was prepared according to the literature procedure[34] and general procedure E. ^{1}H NMR (DMSO-d_6, 500 MHz): δ = 6.95 (s, 2H), 6.82 (d, J = 1.5 Hz, 1H), 4.06 (s, 2H), 3.59 (t, J = 6.0 Hz, 1H), 2.63−2.62 (m, 2H). ^{13}C NMR (DMSO-d_6, 125 MHz): δ = 152.1, 134.7 × 2, 116.4, 112.9 × 2, 45.0, 43.0 ppm. MS (ESI): m/z 284.0 [M + H]$^+$. CHN calculated for $C_{12}H_{11}Cl_2N_3O$: C, 50.72; H, 3.90; N, 14.79. Found: C, 50.53; H, 4.03; N, 14.83.

6-(3,5-Dichlorophenyl)-4,5,6,7-tetrahydro-1*H*-pyrazolo[3,4-c]pyridin-3(2*H*)-one (28). The title compound was prepared according to the literature procedure[34] and general procedure E. ^{1}H NMR (DMSO-d_6, 500 MHz): δ = 6.96 (d, J = 1.5 Hz, 2H), 6.83 (d, J = 1.5 Hz, 1H), 4.26 (s, 2H), 3.55 (t, J = 6.0 Hz, 2H), 3.16 (d, J = 5.0 Hz, 1H), 2.41−2.39 (m, 2H). ^{13}C NMR (DMSO-d_6, 125 MHz): δ = 152.0, 134.7 × 2, 116.6, 113.1 × 2, 46.2, 29.5, 18.6 ppm. MS (ESI): m/z 284.0 [M + H]$^+$. CHN calculated for $C_{12}H_{11}Cl_2N_3O$: C, 50.72; H, 3.90; N, 14.79. Found: C, 50.51; H, 3.78; N, 14.57.

2-Benzyl-5-(((3,5-dichlorophenyl)(methyl)amino)methyl)-1*H*-pyrazol-3(2*H*)-one (29). To a solution of ethyl 4-((3,5-dichlorophenyl)(methyl)amino)-3-oxobutanoate (304 mg, 1.0 mmol) and benzylhydrazine dihydrochloride (388 mg, 2.0 mmol) in EtOH (5 mL) was added anhydrous triethylamine (570 uL, 4.0 mmol). The resulting solution was stirred at room temperature overnight. After evaporation of the volatiles, the residue was purified on a silica gel column, eluting with a mixture of MeOH and dichloromethane (1−2% MeOH) to afford the product as a pale yellow solid (320 mg, 88%). The solid was then recrystallized in dichloromethane/hexane to give the product as a white solid. ^{1}H NMR (DMSO-d_6, 500 MHz): δ = 11.00 (br s, 1H), 7.28 (t, J = 7.0 Hz, 2H), 7.23 (d, J = 7.0 Hz, 1H), 7.11 (d, J = 7.0 Hz, 2H), 6.74 (d, J = 1.5 Hz, 2H), 6.69 (s, 1H), 5.12 (s, 1H), 5.01 (s, 2H), 4.33 (s, 2H), 2.98 (s, 2H). ^{13}C NMR (DMSO-d_6, 125 MHz): δ = 152.7, 151.0, 146.8, 138.0, 134.4 × 2, 128.4 × 2, 127.1, 127.0 × 2, 114.4, 110.6 × 2, 84.6, 50.3, 49.2, 38.9 ppm. MS (ESI): m/z 284.0 [M + H]$^+$. CHN calculated for $C_{18}H_{17}Cl_2N_3O$: C, 59.68; H, 4.73; N, 11.60. Found: C, 59.79; H, 4.68; N, 11.48.

5-(((3,5-Dichlorophenyl)(methyl)amino)methyl)-2-methyl-1*H*-pyrazol-3(2*H*)-one (30). To a solution of ethyl 4-((3,5-dichlorophenyl)(methyl)amino)-3-oxobutanoate (304 mg, 1.0 mmol) in EtOH (5 mL) was added anhydrous methylhydrazine (105 μL, 2.0 mmol). The resulting solution was stirred at room temperature overnight. After evaporation of the volatiles, the residue was purified on a silica gel column, eluting with a mixture of MeOH and dichloromethane (2−10% MeOH) to afford the product as a pale yellow solid (231 mg, 81%). The solid was then recrystallized in dichloromethane/hexane to give the product as a white solid. ^{1}H NMR (DMSO-d_6, 500 MHz): δ = 6.72 (d, J = 1.5 Hz, 2H), 6.68 (t, J = 1.5 Hz, 1H), 5.13 (s, 1H), 4.29 (s, 2H), 3.43 (s, 3H), 2.95 (s, 3H). ^{13}C NMR (DMSO-d_6, 125 MHz): δ = 152.5, 151.0, 146.0, 134.4 × 2, 114.3, 110.4 × 2, 84.5, 49.9, 38.5, 33.0 ppm. MS (ESI): m/z 286.1 [M + H]$^+$. CHN calculated for $C_{12}H_{13}Cl_2N_3O$: C, 50.37; H, 4.58; N, 14.68. Found: C, 50.60; H, 4.65; N, 14.62. FTIR (solid), ν 1591, 1552, 1495, 1445, 1309, 1272, 1094, 1012, 980, 950, 813, 756, 662 cm^{-1}; (DMSO), ν 1591, 1552, 1436, 1309, 1042 (bw), 950, 806, 756, 697, 663 cm^{-1}.

5-(((3,5-Dichlorophenyl)(methyl)amino)methyl)-1-methyl-1H-pyrazol-3(2H)-one (31). Compound 37 (115 mg, 0.37 mmol) was suspended in 2 N HCl (7 mL) and stirred at 60 °C overnight. Ethyl acetate was added to the mixture, and the organic layer was separated, washed with water and brine, dried over Na_2SO_4, and concentrated. The residue was purified on a silica gel column, eluting with a mixture of MeOH and dichloromethane (4% MeOH) to afford the product as a white solid (55 mg, 52%). ¹H NMR (DMSO-d_6, 500 MHz): δ = 9.42 (s, 1H), 6.75 (m, 3H), 5.08 (s, 1H), 4.54 (s, 2H), 3.52 (s, 3H), 2.94 (s, 3H). ¹³C NMR (DMSO-d_6, 125 MHz): δ = 159.5, 150.8, 139.4, 134.6 × 2, 115.0, 110.7 × 2, 89.7, 46.9, 38.2, 35.7 ppm. MS (ESI): m/z 286.1 [M + H]⁺. CHN calculated for $C_{12}H_{13}Cl_2N_3O$: C, 50.37; H, 4.58; N, 14.68. Found: C, 50.57; H, 4.73; N, 14.74. FTIR (solid), ν 1587, 1552, 1493, 1447, 1345, 1125, 1098, 1018, 959, 813, 801, 774, 663 cm⁻¹; (DMSO), ν 1587, 1552, 1493, 1435, 1282, 1043 (bw), 952, 800, 697, 664 cm⁻¹.

5-(((3,5-Dichlorophenyl)(methyl)amino)methyl)-1,2,4-trimethyl-1H-pyrazol-3(2H)-one (32). A solution of compound 30 (200 mg, 0.7 mmol), MeI (132 μL, 2.1 mmol), and K_2CO_3 (290 mg, 2.1 mmol) in acetonitrile (3.5 mL) was stirred at 50 °C for 24 h. After evaporation of the volatiles, the residue was purified on a silica gel column, eluting with a mixture of MeOH and dichloromethane (1−5% MeOH) to afford the product (compounds 32−34) as a pale yellow solid or liquid. ¹H NMR (CDCl₃, 500 MHz): δ = 6.78 (t, J = 1.5 Hz, 1H), 6.65 (d, J = 1.5 Hz, 2H), 4.23 (s, 2H), 3.32 (s, 3H), 3.08 (s, 3H), 2.82 (s, 3H), 1.86 (s, 3H). ¹³C NMR (CDCl₃, 125 MHz): δ = 166.5, 151.1, 147.3, 136.0 × 2, 118.2, 111.9 × 2, 108.7, 46.7, 37.6, 35.0, 29.1, 7.27 ppm. MS (ESI): m/z 314.1 [M + H]⁺.

5-(((3,5-Dichlorophenyl)(methyl)amino)methyl)-1,2-dimethyl-1H-pyrazol-3(2H)-one (33). ¹H NMR (CDCl₃, 500 MHz): δ = 6.76 (t, J = 1.5 Hz, 1H), 6.57 (d, J = 2.0 Hz, 2H), 5.28 (s, 1H), 4.27 (s, 2H), 3.38 (s, 3H), 3.25 (s, 3H), 2.96 (s, 3H). ¹³C NMR (CDCl₃, 125 MHz): δ = 166.0, 151.4, 150.4, 135.9 × 2, 118.0, 111.4 × 2, 98.1, 49.0, 38.7, 34.2, 28.8 ppm. MS (ESI): m/z 300.1 [M + H]⁺.

3-(((3,5-Dichlorophenyl)(methyl)amino)methyl)-1,4,4-trimethyl-1H-pyrazol-5(4H)-one (34). ¹H NMR (CDCl₃, 500 MHz): δ = 6.72 (t, J = 1.5 Hz, 1H), 6.58 (d, J = 1.5 Hz, 2H), 4.17 (s, 2H), 3.30 (s, 3H), 3.00 (s, 3H), 1.23 (s, 6H). ¹³C NMR (CDCl₃, 125 MHz): δ = 178.4, 162.6, 150.6, 135.8 × 2, 117.2, 110.9 × 2, 50.6, 48.0, 39.3, 31.5, 21.3 ppm. MS (ESI): m/z 314.1 [M + H]⁺.

3,5-Dichloro-N-((2,3-dihydropyrazolo[5,1-b]oxazol-6-yl)methyl)-N-methylaniline (36). To a solution of ethyl 4-(((3,5-dichlorophenyl)(methyl)amino)-3-oxobutanoate (304 mg, 1.0 mmol) in EtOH (5 mL) was added 2-hydroxyethylhydrazine (85 uL, 1.1 mmol), and the mixture was stirred for 3 h. After evaporation of the volatiles, the residues were dissolved with dry acetonitrile (10 mL) and triethylamine (156 uL, 1.1 mmol) followed by the addition of tosyl chloride (190 mg, 1.0 mmol). The solution was stirred for 20 min, diluted with ethyl acetate (20 mL), washed with water (10 mL), dried over Na_2SO_4, and concentrated. The residue was purified on a silica gel column, eluting with a mixture of MeOH and dichloromethane (2% MeOH) to afford the product as a pale yellow liquid 35 (400 mg, 85%).

Under an inert atmosphere, 35 was dissolved in anhydride acetonitrile (8.5 mL) followed by the addition of sodium hydride (40 mg, 1.0 mmol). The mixture was stirred overnight at room temperature and evaporated to give the residue, which was purified on a silica gel column, eluting with a mixture of MeOH and dichloromethane (1% MeOH) to afford the product as a pale yellow solid 36 (200 mg, 79%). ¹H NMR (CDCl₃, 500 MHz): δ = 6.66 (d, J = 1.5 Hz, 1H), 6.63 (d, J = 1.5 Hz, 2H), 5.19 (s, 1H), 5.00 (dd, J = 7.5, 9.0 Hz, 2H), 4.36 (s, 2H), 4.25 (t, J = 7.5 Hz, 2H), 2.99 (s, 3H). ¹³C NMR (CDCl₃, 125 MHz): δ = 159.7, 155.0, 151.0, 135.6 × 2, 116.4, 111.0 × 2, 79.5, 75.3, 51.6, 45.4, 38.8 ppm. MS (ESI): m/z 298.0 [M + H]⁺.

5-(((3,5-Dichlorophenyl)(methyl)amino)methyl)-1-methyl-2-vinyl-1H-pyrazol-3(2H)-one (37). To a solution of compound 36 (200 mg, 0.67 mmol) in anhydrous acetonitrile (6 mL) was added methyl trifluoromethanesulfonate (85 μL, 0.75 mmol), and the solution was stirred for 2 h before the addition of sodium iodide

(195 mg, 1.3 mmol) and TsOH (127 mg, 0.67 mmol). After conversion to the iodinated intermediate by overnight stirring, KO-t-Bu (188 mg, 1.7 mmol) was added to the mixture, which was further stirred for 1 h. After evaporation of the volatiles, the residue was purified on a silica gel column, eluting with a mixture of MeOH and dichloromethane (4% MeOH) to afford the product as a yellow liquid (115 mg, 55%). ¹H NMR (CDCl₃, 500 MHz): δ = 6.85 (dd, J = 9.0, 16.0 Hz, 1H), 6.77 (t, J = 1.5 Hz, 2H), 6.56 (d, J = 1.5 Hz, 2H), 5.37 (s, 1H), 4.88−4.80 (m, 2H), 4.31 (s, 2H), 3.17 (s, 3H), 2.99 (s, 3H). ¹³C NMR (CDCl₃, 125 MHz): δ = 165.4, 159.2, 150.3, 136.0 × 2, 126.3, 118.0, 111.3 × 2, 101.1, 99.5, 49.6, 39.0, 37.3 ppm.

Mutant SOD1-Induced Cytotoxicity Protection Assay. Viability and EC_{50} values were determined for 1a, 1b, 2a, and 2b according to the previously reported assay procedure.[15] PC12 cells were seeded at 15 000 cells/well in 96-well plates and incubated 24 h prior to compound addition. Compounds were assayed in 12-point dose−response experiments to determine potency and efficacy. The highest compound concentration tested was 32 μM, which was decreased by one-half with each subsequent dose. After a 24 h incubation with the compounds, MG132 was added at a final concentration of 100 nM. MG132 is a well-characterized proteasome inhibitor, which would be expected to enhance the appearance of protein aggregation by blocking the proteosomal clearance of aggregated proteins. Cell viability was measured 48 h later using the fluorescent viability probe Calcein-AM (Molecular Probes). Briefly, cells were washed twice with PBS. Calcein-AM was added at a final concentration of 1 μM for 20 min at room temperature, and fluorescence intensity was read in a POLARstar fluorescence plate reader (BMG). Fluorescence data were coupled with compound structural data, then stored and analyzed using the CambridgeSoft Chemoffice Enterprise Ultra software package.

In Vitro ADME Assays. In vitro microsomal stability, aqueous solubility, and Caco-2 permeability were determined for 1b and 2b at Apredica Inc. (Watertown, MA).

Computational Methods. Possible initial tautomer structures were constructed with molecular modeling software Sybyl-X 1.2 (Tripos International, St. Louis, MO). After primary optimization by use of MM2 molecular mechanical module encoded in the program CS Chem3D, these two structures were subjected to full optimization within the density-functional theory (DFT). The Lee−Yang−Parr correlation functional approximation (B3LYP) method was used in a 6-31+G(d,p) basis set.[35,36] On the basis of the optimized geometries, energy or frequency calculations were carried out at the same levels of B3LYP to verify the reasonability of the optimized structures. A frequency scaling factor of 0.964 was used in the comparison of the calculated results with the experimental spectra.[37] All of the Quantum Chemical calculations were carried out with the Gamess (2012R1) program.[38]

ASSOCIATED CONTENT

Ⓢ Supporting Information

NMR spectra for compounds 2−38, IR spectra for compounds 30, 31, and 38, and primary cortical neuron protection assay for compounds 1, 3, 19−21, 23, 24, and 27. This material is available free of charge via the Internet at http://pubs.acs.org.

AUTHOR INFORMATION

Corresponding Author
*Phone: 847-491-5663. Fax: 847-491-7713. E-mail: Agman@chem.northwestern.edu.

Present Address
‖For C.V.: Department of Biology, Northeastern Illinois University, Chicago, IL 60625, U.S.

Notes
The authors declare no competing financial interest.

■ ABBREVIATIONS USED

AAP, arylazanylpyrazolone; ADME, absorption, distribution, metabolism, excretion; ALS, amyotrophic lateral sclerosis; ASP, arylsulfanylpyrazolone; AXP, aryl heteroatom pyrazolone; CNS, central nervous system; DFT, density functional theory; FALS, familial amyotrophic lateral sclerosis; IR, infrared spectroscopy; NOE, nuclear Overhauser effect; PBS, phosphate buffered saline; PK, pharmacokinetics; SALS, sporadic amyotrophic lateral sclerosis; SOD1, Cu/Zn superoxide dismutase

■ REFERENCES

(1) Rowland, L. P.; Shneider, N. A. Amyotrophic lateral sclerosis. *N. Engl. J. Med.* **2001**, *344*, 1688−1700.

(2) Rothstein, J. D. Currenthypothese for the underlying biology of amyotrophic lateral sclerosis. *Ann. Neurol.* **2009**, *65* (Suppl. 1), S3−S9.

(3) Worms, P. M. The epidemiology of motor neuron diseases: a review of recent studies. *J. Neurol.Sci.* **2001**, *191*, 3−9.

(4) Weisskopf, M. G.; O'Reilly, E. J.; McCullough, M. L.; Calle, E. E.; Thun, M. J.; Cudkowicz, M.; Ascherio, A. Prospective study of military service and mortality from ALS. *Neurology* **2005**, *64*, 32−37.

(5) Mitsumoto, H.; Rabkin, J. G. Palliative care for patients with amyotrophic lateral sclerosis: "Prepare for the worst and hope for the best". *JAMA, J. Am. Med. Assoc.* **2007**, *298*, 207−216.

(6) Waldmeier, P. C.; Tatton, W. G. Interrupting apoptosis in neurodegenerative disease: potential for effective therapy? *Drug Discovery Today* **2004**, *9*, 210−218.

(7) Bensimon, G.; Lacomblez, L.; Meininger, V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. *N. Engl. J. Med.* **1994**, *330*, 585−591.

(8) ALS Online Genetics Database: http://alsod.iop.kcl.ac.uk/.

(9) Rosen, D. R.; Siddique, T.; Patterson, D.; Figlewicz, D. A.; Sapp, P.; et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. *Nature* **1993**, *362*, 59−62.

(10) Turner, B. J.; Talbot, K. Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS. *Prog. Neurobiol.* **2008**, *85*, 94−134.

(11) Nagai, M.; Re, D. B.; Nagata, T.; Chalazonitis, A.; Jessell, T. M.; Wichterle, H.; Przedborski, S. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. *Nat. Neurosci* **2007**, *10*, 615−622.

(12) Haidet-Phillips, A. M.; Hester, M. E.; Miranda, C. J.; Meyer, K.; Braun, L.; Frakes, A.; Song, S. W.; Likhite, S.; Murtha, M. J.; Foust, K. D.; Rao, M.; Eagle, A.; Kammesheidt, A.; Christensen, A.; Mendell, J. R.; Burghes, A. H. M.; Kaspar, B. K. Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. *Nat. Biotechnol.* **2011**, *29*, 824−830.

(13) Gruzman, A.; Wood, W. L.; Alpert, E.; Prasad, M. D.; Miller, R. G.; Rothstein, J. D.; Bowser, R.; Hamilton, R.; Wood, T. D.; Cleveland, D. W.; Lingappa, V. R.; Liu, J. Common molecular signature in SOD1 for both sporadic and familial amyotrophic lateral sclerosis. *Proc. Natl. Acad. Sci. U.S.A.* **2007**, *104*, 12524−12529.

(14) Matsumoto, G.; Stojanovic, A.; Holmber, C. I.; Kim, S.; Morimoto, R. I. Structure properties and neuronal toxicity of amyotrophic lateral sclerosis-associated Cu/Zn superoxide dismutase 1 aggregates. *J. Cell Biol.* **2005**, *171*, 75−85.

(15) Benmohamed, R.; Arvanites, A. C.; Silverman, R. B.; Morimoto, R. I.; Ferrante, R. J.; Kirsch, D. R. Identification of compounds protective against G93A SOD1 toxicity for the treatment of amyotrophic lateral sclerosis. *Amyotrophic Lateral Scler.* **2011**, *12*, 87−96.

(16) Chen, T.; Benmohamed, R.; Arvanites, A. C.; Ranaivo, H. R.; Morimoto, R. I.; Ferrante, R. J.; Watterson, D. M.; Kirsch, D. R.; Silverman, R. B. Arylsulfanyl pyrazolones block mutant SOD1-G93A aggregation. Potential application for the treatment of amyotrophic lateral sclerosis. *Bioorg. Med. Chem.* **2011**, *19*, 613−622.

(17) Chen, T.; Benmohamed, R.; Kim, J.; Smith, K.; Amante, D.; Morimoto, R. I.; Ferrante, R. J.; Kirsch, D.; Silverman, R. B. ADME-guided design and synthesis of aryloxanylpyrazonlone derivatives to block mutant superoxide dismutase 1 (SOD1) cytotoxicity and protective aggregation: potential application for the treatment of amyotrophic lateral sclerosis. *J. Med. Chem.* **2012**, *55*, 515−527.

(18) Trippier, P. C.; Benmohammed, R.; Kirsch, D. R.; Silverman, R. B. Substituted pyrazolones require N^2 hydrogen bond donating ability to protect against cytotoxicity from protein aggregation of mutant superoxide dismutase 1. *Bioorg. Med. Chem. Lett.* **2012**, *22*, 6647−6650.

(19) Zhang, Y.; Silverman, R. Direct amination of γ-halo-β-ketoesters with anilines. *J. Org. Chem.* **2012**, *77*, 3462−3467.

(20) Yang, M.; Wang, X.; Li, H.; Livant, P. A new route to hindered tertiary amines. *J. Org. Chem.* **2001**, *66*, 6729−6733.

(21) Hamper, B. C.; Kurtzweil, M. L.; Beck, J. P. Cyclocodensation of alkyl hydrazines and β-substituted acetylenic esters: synthesis of 3-hydroxypyrazoles. *J. Org. Chem.* **1992**, *57*, 5680−5686.

(22) Zimmermann, D.; Krogsgaard-Larsen, P.; Ehrhard, J. -D.; Madsen, U.; Janin, Y. L. Unambiguous synthesis of 1-methyl-3-hydroxypyrazoles. *Tetrahedron* **1998**, *54*, 9393−9400.

(23) Kerns, E. H.; Di, L. *Drug-like Properties: Concepts, Structure, Design, and Methods*; Academic Press: Amsterdam, 2008; p 65.

(24) Van de Waterbeemd, H.; Gifford, E. ADMET in silico modeling: towards prediction paradise? *Nat. Rev. Drug Dicovery* **2003**, *2*, 192−204.

(25) Compound **1**, which had an EC_{50} of 0.067 μM in the protection assay in our earlier report of aryloxanyl pyrazolones, showed an average activity of 0.4 μM for several parallel repeats in this study.

(26) Park, K. D.; Kim, D.; Reamtong, O.; Eyers, C.; Gaskell, S. J.; Liu, R.; Kohn, H. Identification of a lacosamide binding protein using an affinity bait and chemical reporter strategy: 14-3-3ζ. *J. Am. Chem. Soc.* **2011**, *133*, 11320−11330.

(27) Silverman, R. B. *The Organic Chemistry of Drug Design and Drug Action*, 2nd ed.; Elsevier Academic Press: Amsterdam, 2004; p 28.

(28) Zhang, Y.; Benmohamed, R.; Zhang, W.; Kim, J.; Edgerly, C. K.; Zhu, Y.; Morimoto, R. I.; Ferrante, R. J.; Kirsch, D. R.; Silverman, R. B. Chiral cyclohexane 1,3-diones as inhibitors of mutant SOD1-dependent protein aggregation for the treatment of amyotrophic lateral sclerosis. *ACS Med. Chem. Lett.* **2012**, *3*, 584−587.

(29) Knorr, L. Ueber abkommlinge der phenol form des 1-phenyl-3-methyl-5-pyrazolons. *Ber. Dtsch. Chem. Ges.* **1895**, *28*, 706−714.

(30) (a) Parchment, O. G.; Green, D. V. S.; Taylor, P. J.; Hillier, I. H. The prediction of tautomer equilibria in hydrated 3-hydroxypyrazole: a challenge to theory. *J. Am. Chem. Soc.* **1993**, *115*, 2352−2356. (b) Enchev, V.; Neykov, G. D. A semiempirical and ab initio MO study of the tautomers of N-unsubstituted pyrazolones (hyroxy pyrazoles). *Struct. Chem.* **1992**, *3*, 231−238. (c) Nagy, P. I.; Tejada, F. R.; Messer, W. S., Jr. Theoretical studies of the tautomeric equilibria for five-member N-heterocycles in the gas phase and in solution. *J. Phys. Chem. B* **2005**, *109*, 22588−22602.

(31) Hamper, B. Regioselective synthesis of 1-methyl-3-hydroxy-5-perfluoroalkyl pyrazoles by the addition of methylhydrazine to perfluoroalkylacetylenic ester. *J. Fluorine Chem.* **1990**, *48*, 123−131.

(32) Compound **5b** in ref 17.

(33) In procedure C for preparing compound **21**, the reaction time needs to be extended to 16 h while allowing the reaction temperature to rise to room temperature.

(34) Zhang, Y.; Silverman, R. B. An efficient synthesis of 1-aryl-3-piperidione derivative through MBH and RCM reactions. *Tetrahedron Lett.* **2013**, *54*, 573−575.

(35) Becke, A. D. Density-functional thermochemistry. III. The role of exact exchange. *J. Chem. Phys.* **1993**, *98*, 5648−5652.

(36) Lee, C.; Yang, W.; Parr, R. G. Development of the Colle−Salvetti correlation energy formula into a functional of the electron density. *Phys. Rev. B* **1988**, *37*, 785−789.

(37) Merrick, J. P.; Moran, D.; Radom, L. An evaluation of harmonic vibrational frequency scale factors. *J. Phys. Chem. A* **2007**, *111*, 11683−11700.

(38) Schmidt, M. S.; Baldridge, K. K.; Boatz, J. A.; Elbert, S. T.; Gordon, M. S.; Jensen, J. H.; Koseki, S.; Matsunaga, N.; Nguyen, K. A.; Su, S.; Windus, T. L.; Dupuis, M.; Montgomery, J. A. General atomic and molecular electronic structure system. *J. Comput. Chem.* **1993**, *14*, 1347−1363.